7 Indian Pharma Companies are battling for COVID-19 vaccine

7 Indian Pharma Companies are battling for COVID-19 vaccine

In order to work together to find a preventive solution to prevent the spread of the deadly virus that has already infected over 14 million worldwide, at minimum seven Indian pharmaceutical companies are working to create a coronavirus vaccine.

7 Indian Pharma Companies are battling for COVID-19 vaccine

Among domestic pharmaceuticals companies that work on the coronavirus vaccines in India, include Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E.

Vaccines usually take years of research and time to manufacture on a scale, but scientists expect to create a pandemic within months.

Bharat Biotech

For its vaccine candidate Covaxin developed and manufactured at Hyderabad, Bharat Biotech has been approved for the phase I and II clinical trials. Human clinical trials began last week.

A leading Serum Institute vaccine in India has expressed hopes that Covid-19 vaccine will be produced by the end of the year.

‘We ‘re working now on Phase III clinical trial AstraZeneca Oxford vaccine and are also launching human trials in August 2020 in India. We hope the AstraZeneca Oxford vaccine will be available by the end of the year on the basis of the current circumstances and recent clinical trial updates.

Serum Institute

Adar Poonawalla, CEO of the Serum Institute of India, told PTI.

The company is also producing a live attenuated vaccine, which is being pre-clinically tested with US-based biotech firm Codagenix.

“We’ve established several institutions around the world, apart from AstraZeneca Oxford vaccine and Codagenix, as manufacturing partners for vaccine candidates, including Austria’s Themis and two others,” said Poonawalla.

Poonawalla said in collaboration with AstraZeneca: “The Serum Institute of India has formed a manufacturing agreement with AstraZeneca under which Oxford University is developing and distributing 1 billion doses of Covid-19 vaccine.”

These vaccines will be for India and middle and low income countries across the world (GAVI countries), he added.

Zydus Cadila

Zydus Cadila, a Pharma Major, has said it plans to complete the Covid-19 ZyCoV-D clinical trials in seven months.

The company began clinical trials last week of its first human dosing vaccine candidate Covid-19.

In a statement from Zydus Cadila Chairman Pankaj R. Patel, it could take a total of seven months to complete the trials and activate the vaccine, depending on the outcome of the test, and whether the data is positive and the vaccine proved successful during the trials.

Bharat Biotech based in Hyderabad began human testing on its Covaxin vaccine at the Rohtak Institute of Medical Sciences, a post-graduate study last week.

The phase I and II clinical trials of the vaccine for SARS-CoV-2 by Bharat Biotech have been approved by the Indian drug regulator after pre-clinical studies demonstrated safety and immune response.

In partnership between the Indian Medical Research Council (ICMR) and the National Institute of Virology (NIV), the company has developed the vaccine.

Panacea Biotec

In June, Panacea Biotec announced that it had set up a joint venture with Refana Inc, based in the United States, for the production of a Covid-19 vaccine in Ireland.

The company plans to produce more than 500 million doses of candidate COVID 19 vaccine in collaboration with Refana, with over 40 million doses planned in 2021.

In an agreement with Australia’s Griffith University, Indian Immunologicals, a subsidiary of the National Dairy Development Board (NDDB) is developing the coronavirus vaccine. Others such as Mynvax and Biological E also develop Covid-19 vaccines.

In the case of the immune system, vaccines usually contain an antigen with unharmful copies: a part of the bacterial or virus surface recognized as alien by the immune system. A non-active version of a toxin — a toxin made by a bacterium — can also be supplied with a vaccine to help the body defence against it.

They must comply with higher quality requirements than other medications because millions of healthy people are administered.

Vaccine testing is a four-stage method – pre-clinical animal testing and phase I clinical testing of small groups of people for safety and immune response, phase II testing extended safety testing and phase III testing is conducted by thousands of individuals to validate its successful performance.

About 140 candidate vaccines, around two dozen of them in different stages of human clinical trials, are tracked by the World Health Organization (WHO) worldwide.

China’s Sinovac Biotech company in Brazil is in phase III trials, while Oxford / AstraZeneca University in the UK is in a phase II-III combined trial, with phase III studies in South Africa and Brazil recently underway.

Moderna, based in the US, expects its vaccine candidate to begin Phase III this month. German firm BioNTech is partnering with major pharmaceutical firms Pfizer to create a Covid-19 vaccine, among other leading players.

The companies have been quick-track awarded two investigational vaccine candidates, developed by the US Food and Drug Administration (SFDA), to help defend them against SARS-CoV-2.

7 Indian Pharma Companies are battling for COVID-19 vaccine

We will be happy to hear your thoughts

Leave a reply

Bioinformatics India
Logo